Find Alacepril manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

EU WC

EU WC

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 74258-86-9, Cetapril, Du-1219, X39tl7jdpf, 1-(d-3-acetylthio-2-methylpropanoyl)-l-prolyl-l-phenylalanine, N-(1-((s)-3-mercapto-2-methylpropionyl)-l-prolyl)-3-phenyl-l-alanine acetate (ester)
Molecular Formula
C20H26N2O5S
Molecular Weight
406.5  g/mol
InChI Key
FHHHOYXPRDYHEZ-COXVUDFISA-N
FDA UNII
X39TL7JDPF

Alacepril
Alacepril is a long-acting, sulfhydryl-containing angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. As a prodrug, alacepril is rapidly metabolized to captopril; captopril competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II and results in vasodilation. Captopril also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow.
1 2D Structure

Alacepril

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S)-2-[[(2S)-1-[(2S)-3-acetylsulfanyl-2-methylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
2.1.2 InChI
InChI=1S/C20H26N2O5S/c1-13(12-28-14(2)23)19(25)22-10-6-9-17(22)18(24)21-16(20(26)27)11-15-7-4-3-5-8-15/h3-5,7-8,13,16-17H,6,9-12H2,1-2H3,(H,21,24)(H,26,27)/t13-,16+,17+/m1/s1
2.1.3 InChI Key
FHHHOYXPRDYHEZ-COXVUDFISA-N
2.1.4 Canonical SMILES
CC(CSC(=O)C)C(=O)N1CCCC1C(=O)NC(CC2=CC=CC=C2)C(=O)O
2.1.5 Isomeric SMILES
C[C@H](CSC(=O)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O
2.2 Other Identifiers
2.2.1 UNII
X39TL7JDPF
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Aracepril

2. Du 1219

3. Du-1219

4. N-(1-(3-(acetylthio)-2-methyl-1-oxopropyl)-l-prolyl)-l-phenylalanine

2.3.2 Depositor-Supplied Synonyms

1. 74258-86-9

2. Cetapril

3. Du-1219

4. X39tl7jdpf

5. 1-(d-3-acetylthio-2-methylpropanoyl)-l-prolyl-l-phenylalanine

6. N-(1-((s)-3-mercapto-2-methylpropionyl)-l-prolyl)-3-phenyl-l-alanine Acetate (ester)

7. Nsc-338157

8. Ncgc00182037-01

9. Alaceprilum [latin]

10. Alaceprilum

11. Alacepril [inn:jan]

12. 1-[(2s)-3-(acetylthio)-2-methyl-1-oxopropyl]-l-prolyl-l-phenylalanine

13. Cetapril (tn)

14. (s)-2-((s)-1-((s)-3-(acetylthio)-2-methylpropanoyl)pyrrolidine-2-carboxamido)-3-phenylpropanoic Acid

15. Unii-x39tl7jdpf

16. Nsc 338157

17. Du 1219

18. Brn 3634372

19. 1-((2s)-3-(acetylthio)-2-methyl-1-oxopropyl)-l-prolyl-l-phenylalanine

20. Alacepril [inn]

21. Alacepril [jan]

22. Alacepril [mi]

23. N-(2-((s)-3-acetylthio-2-methylpropionyl)propyl)-3-phenylalanin

24. Alacepril (jp17/inn)

25. Alacepril [mart.]

26. Alacepril [who-dd]

27. Dsstox_cid_28502

28. Dsstox_rid_82774

29. Dsstox_gsid_48576

30. Schembl34559

31. Chembl2103775

32. Dtxsid3048576

33. Chebi:31182

34. Zinc3775143

35. Tox21_112904

36. Akos015916655

37. Ks-1321

38. L-phenylalanine, N-(1-(3-(acetylthio)-2-methyl-1-oxopropyl)-l-prolyl)-, (s)-

39. (2s)-2-[[(2s)-1-[(2s)-3-acetylsulfanyl-2-methylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic Acid

40. Cas-74258-86-9

41. Hy-107318

42. Cs-0028129

43. D01900

44. 258a869

45. Q3290792

46. 219554-02-6

2.4 Create Date
2005-06-24
3 Chemical and Physical Properties
Molecular Weight 406.5 g/mol
Molecular Formula C20H26N2O5S
XLogP32.1
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count6
Rotatable Bond Count9
Exact Mass406.15624311 g/mol
Monoisotopic Mass406.15624311 g/mol
Topological Polar Surface Area129 Ų
Heavy Atom Count28
Formal Charge0
Complexity591
Isotope Atom Count0
Defined Atom Stereocenter Count3
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Antihypertensive Agents

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)


Angiotensin-Converting Enzyme Inhibitors

A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)


ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty